[{"Assets_0_FY_USD":61389000.0,"CommonStockSharesOutstanding_0_FY_shares":10799895.0,"NetCashProvidedByUsedInOperatingActivities_4_FY_USD":10558000.0,"NetIncomeLoss_1_FY_USD":-657000.0,"NetIncomeLoss_4_FY_USD":-15805000.0,"StockholdersEquity_0_FY_USD":27253000.0,"Assets_0_Q1_USD":57618000.0,"CommonStockSharesOutstanding_0_Q1_shares":10799895.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-6212000.0,"NetIncomeLoss_1_Q1_USD":-5030000.0,"StockholdersEquity_0_Q1_USD":26250000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":3718000.0,"Ticker":"KALV","CIK":"1348911","name":"KALVISTA PHARMACEUTICALS, INC.","OfficialName":"KalVista Pharmaceuticals Inc. Common Stock","form":"10-K","period":"20180430","fy":"2018.0","fp":"FY","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"339433230.0","Country":"United Kingdom","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180914"}]